<p>根据 Securities and Exchange Commission (SEC) 最近的 13F 表格，SBI 证券有限公司在第二季度将其在 Seres Therapeutics, Inc.（NASDAQ:MCRB - 免费报告）股票中的持仓削减了 95.0%。该公司在此期间出售了 66,182 股后，持有 3,482 股生物技术公司的股票。截至其最近的 SEC 文件，SBI 证券有限公司在 Seres Therapeutics 的持股价值为 39,000 美元。</p>
<p>另外，高盛集团在第一季度将其在 Seres Therapeutics 的股份增加了 40.9%。高盛集团目前拥有 74,629 股生物技术公司的股票，价值 52,000 美元，此前在此期间又购买了 21,679 股。目前，59.34% 的股票由机构投资者持有。</p>
<p>获取 <strong>Seres Therapeutics</strong> 的提醒：</p>
<h2>Seres Therapeutics 股价上涨 14.2%</h2>
<p>周三，MCRB 的开盘价为 24.71 美元。该股票的 50 日简单移动平均为 17.86 美元，200 日简单移动平均为 14.08 美元。该股票的市值为 2.2363 亿美元，市盈率为-5.48，贝塔值为 0.19。Seres Therapeutics, Inc.的 1 年最低价为 6.53 美元，1 年最高价为 25.85 美元。</p>
<h2>分析师设定新的价格目标</h2>
<p>MCRB 已成为多份研究分析师报告的主题。Canaccord Genuity Group 将 Seres Therapeutics 的价格目标从 14.00 美元上调至 22.00 美元，并在 9 月 24 日的报告中给予该股票 “买入” 评级。Weiss Ratings 在周一的研究报告中重申了对 Seres Therapeutics 股票的 “卖出（d）” 评级。一位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “减持”，共识目标价为 14.33 美元。</p>
<p><strong>阅读我们关于 MCRB 的最新报告</strong></p>
<h2>Seres Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Seres Therapeutics, Inc.是一家微生物组治疗公司，开发微生物组治疗以调节结肠微生物组。它开发了一类新型生物药物，旨在通过调节微生物组来恢复健康，修复功能失调的微生物组，使其恢复到非疾病状态。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Seres Therapeutics</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>现在值得购买的 3 只巨型成长股</li>
<li>高通的牛市空间正在缩小</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Seres Therapeutics 吗？</h2>
<p>在考虑 Seres Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Seres Therapeutics 并不在名单上。</p>
<p>虽然 Seres Therapeutics 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Seres治疗

<p>SBI 证券有限公司在第二季度将其在 Seres Therapeutics, Inc.的持股比例减少了 95%，目前持有 3,482 股，价值 39,000 美元。高盛在第一季度将其持股比例增加了 40.9%，拥有 74,629 股，估值为 52,000 美元。Seres Therapeutics 的股票上涨了 14.2%，市值为 2.2363 亿美元。分析师的评级意见不一，普遍目标价为 14.33 美元</p>

<p>SBI Securities Co. Ltd. trimmed its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 95.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,482 shares of the biotechnology company's stock after selling 66,182 shares during the period. SBI Securities Co. Ltd.'s holdings in Seres Therapeutics were worth $39,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Securities and Exchange Commission (SEC) 最近的 13F 表格，SBI 证券有限公司在第二季度将其在 Seres Therapeutics, Inc.（NASDAQ:MCRB - 免费报告）股票中的持仓削减了 95.0%。该公司在此期间出售了 66,182 股后，持有 3,482 股生物技术公司的股票。截至其最近的 SEC 文件，SBI 证券有限公司在 Seres Therapeutics 的持股价值为 39,000 美元。</p>
</div><p>Separately, Goldman Sachs Group Inc. boosted its stake in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares during the period. 59.34% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>另外，高盛集团在第一季度将其在 Seres Therapeutics 的股份增加了 40.9%。高盛集团目前拥有 74,629 股生物技术公司的股票，价值 52,000 美元，此前在此期间又购买了 21,679 股。目前，59.34% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Seres Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Seres Therapeutics</strong> 的提醒：</p>
</div><h2>Seres Therapeutics Trading Up 14.2%</h2>
<div class="lb-trans"><h2>Seres Therapeutics 股价上涨 14.2%</h2>
</div><p>MCRB opened at $24.71 on Wednesday. The stock's 50 day simple moving average is $17.86 and its 200-day simple moving average is $14.08. The stock has a market cap of $223.63 million, a PE ratio of -5.48 and a beta of 0.19. Seres Therapeutics, Inc. has a 1 year low of $6.53 and a 1 year high of $25.85.</p>
<div class="lb-trans"><p>周三，MCRB 的开盘价为 24.71 美元。该股票的 50 日简单移动平均为 17.86 美元，200 日简单移动平均为 14.08 美元。该股票的市值为 2.2363 亿美元，市盈率为-5.48，贝塔值为 0.19。Seres Therapeutics, Inc.的 1 年最低价为 6.53 美元，1 年最高价为 25.85 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>MCRB has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their price target on Seres Therapeutics from $14.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Seres Therapeutics in a research note on Monday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $14.33.</p>
<div class="lb-trans"><p>MCRB 已成为多份研究分析师报告的主题。Canaccord Genuity Group 将 Seres Therapeutics 的价格目标从 14.00 美元上调至 22.00 美元，并在 9 月 24 日的报告中给予该股票 “买入” 评级。Weiss Ratings 在周一的研究报告中重申了对 Seres Therapeutics 股票的 “卖出（d）” 评级。一位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “减持”，共识目标价为 14.33 美元。</p>
</div><p><strong>Read Our Latest Report on MCRB</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MCRB 的最新报告</strong></p>
</div><h2>Seres Therapeutics Profile</h2>
<div class="lb-trans"><h2>Seres Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.</p>
<div class="lb-trans"><p>Seres Therapeutics, Inc.是一家微生物组治疗公司，开发微生物组治疗以调节结肠微生物组。它开发了一类新型生物药物，旨在通过调节微生物组来恢复健康，修复功能失调的微生物组，使其恢复到非疾病状态。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Seres Therapeutics</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>What’s on the Thanksgiving Table? A Stock Pick for Every Course</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>Qualcomm’s Bulls Are Running Out of Room to Be Wrong</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Seres Therapeutics</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>感恩节餐桌上有什么？每道菜的股票选择</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>为什么家得宝的痛苦可能是长期投资者的收益</li>
<li>现在值得购买的 3 只巨型成长股</li>
<li>高通的牛市空间正在缩小</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUNSQg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MCRB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Seres Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Seres Therapeutics 吗？</h2>
</div><p>Before you consider Seres Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Seres Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Seres Therapeutics 并不在名单上。</p>
</div><p>While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Seres Therapeutics 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SBI 证券有限公司在 Seres 治疗公司（Seres Therapeutics, Inc.）中持有价值 39,000 美元的股份